Loading company…
Medisix Therapeutics develops T-cell therapies, including its PEBL technology for enhancing CAR T-cell treatments.
Founded in 2016 and based in Singapore, Medisix Therapeutics develops T-cell therapies for rare and complex T-cell malignancies, with its PEBL (Protein Expression BLocker) technology aimed at T-cell acute lymphoblastic leukemia. Andrew Bruce is CEO. The company has raised a total of USD 20.36 mn, most recently in a round completed on September 17, 2019, and reported zero revenue and an EBITDA loss of USD 28,763,317 in 2023.
Funding rounds, investors and people for this company come from licensed data. A free account shows the first rows of each section; an approved contribution opens every profile in full.
Sign in